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Background: Allogeneic stem cell transplantation (alloSCT)
for multiple myeloma (MM) can offer prolonged remission
and may have curative potential. Overproduction of the dis-
ease speciﬁc clonal serum free light chains by malignant
plasma cells (involved free light chain, iFLC) is a marker of
disease activity. Underproduction of the uninvolved serum free
light chain (uFLC, from non-malignant plasma cells) is a
marker of MM mediated immune suppression. Early predic-
tion of relapse after allogeneic SCT remains a challenge, and is
important for prognostic and therapeutic purposes. We hy-
pothesized that sustained iFLC suppression at 12months post-
alloSCT would be associated with improved survival.
Methods: The primary cohort was 50 consecutive patients
treated with allogeneic SCT from two institutions. This was
selected from a total of 60 patients with patients excluded for
death (n¼6) or relapse (n¼4) prior to one year. Data was
collected retrospectively 2005-2010 and then prospectively
from 2010-2012. Baseline and follow-up serum FLC (at 3
month intervals) were correlated with overall survival (OS).
Patients were considered to have a “suppressed” FLC if the
serum iFLC was reduced below the uninvolved FLC at 12
months post-alloSCT. OS was measured from 12 months
post-alloSCT using Kaplan-Meier plots and the 2 groups werecompared using log-rank test. A step-wise backward cox-
proportional hazards model was used adjusting for age,
CD34+ stem cell dose, conditioning regimen (myeloablative
vs. reduced intensity), graft versus host disease prior to one
year, disease risk by FISH (standard vs. high risk), Interna-
tional Staging System (standard risk vs. high risk) and disease
status prior to SCT (complete remission vs. no complete
remission).
Results: Median follow-up time was 40.0 months from
transplant (12-95.6 months). Longer duration of iFLC sup-
pression was associated with superior outcomes. Patients
without sustained iFLC suppression at one year post-SCT had
worse OS (p¼0.03, Figure 1). The 2-y OS in the sustained iFLC
suppression cohort (95% [95% CI 86-NA]) was signiﬁcantly
superior to the non-sustained iFLC suppression cohort (70%
[95% CI 57-99]) (P¼0.03, Figure 1). By univariate analysis,
there were no baseline characteristic differences. By multi-
variate analysis, lack of iFLC suppression at 1-year post-
alloSCT was associated with signiﬁcantly increased mortality
(HR 7.01, 95% CI 1.21-40.8, p¼0.03). Patients with iFLC re-
covery prior to one year had increased relapse risk compared
to sustained iFLC suppression (HR 10.4, 95% CI 2.95-36.6,
p¼0.0003).
Conclusions: Sustained serum iFLC suppression at one year
relative to the uFLC is a predictive marker of outcomes
following alloSCT for MM. Early recovery of iFLC may be an
indicator of disease progression following alloSCT, thus
identifying patients who may beneﬁt from preemptive in-
terventions to prevent post-transplant relapse.78
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